Stephan A Hahn

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7590977/publications.pdf

Version: 2024-02-01

138 papers	12,855 citations	38720 50 h-index	23514 111 g-index

144 all docs	144 docs citations	144 times ranked	14608 citing authors

#	Article	IF	Citations
1	DPC4, A Candidate Tumor Suppressor Gene at Human Chromosome 18q21.1. Science, 1996, 271, 350-353.	6.0	2,180
2	Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nature Genetics, 1994, 8, 27-32.	9.4	1,063
3	MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene, 2007, 26, 4442-4452.	2.6	617
4	Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nature Genetics, 1996, 13, 343-346.	9.4	580
5	Small molecule inhibition of the KRASâ€“PDEÎ´ interaction impairs oncogenic KRAS signalling. Nature, 2013, 497, 638-642.	13.7	551
6	BRCA2 Germline Mutations in Familial Pancreatic Carcinoma. Journal of the National Cancer Institute, 2003, 95, 214-221.	3.0	457
7	The tumor suppressor gene Smad4/Dpc4 is required for gastrulation and later for anterior development of the mouseâ€‰embryo. Genes and Development, 1998, 12, 107-119.	2.7	448
8	Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. Nature Medicine, 2015, 21, 1163-1171.	15.2	349
9	Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. Blood, 2011, 117, 3140-3146.	0.6	284
10	Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 9624-9629.	3.3	236
11	Allelic Loss Is Often the First Hit in the Biallelic Inactivation of the p53 and DPC4 Genes During Pancreatic Carcinogenesis. American Journal of Pathology, 2001, 158, 1677-1683.	1.9	217
12	Analysis of MicroRNAs in Pancreatic Fine-Needle Aspirates Can Classify Benign and Malignant Tissues. Clinical Chemistry, 2008, 54, 1716-1724.	1.5	194
13	HNPCC-associated small bowel cancer: Clinical and molecular characteristics. Gastroenterology, 2005, 128, 590-599.	0.6	186
14	Transcriptome analysis of microdissected pancreatic intraepithelial neoplastic lesions. Oncogene, 2005, 24, 6626-6636.	2.6	174
15	Identification of microRNAs in the cerebrospinal fluid as biomarker for the diagnosis of glioma. Neuro-Oncology, 2012, 14, 29-33.	0.6	174
16	Expression of microRNAs in basal cell carcinoma. British Journal of Dermatology, 2012, 167, 847-855.	1.4	172
17	MiR-30a-5p suppresses tumor growth in colon carcinoma by targeting DTL. Carcinogenesis, 2012, 33, 732-739.	1.3	160
18	CDKN2A Germline Mutations in Familial Pancreatic Cancer. Annals of Surgery, 2002, 236, 730-737.	2.1	157

#	Article	IF	Citations
19	Identification by representational difference analysis of a homozygous deletion in pancreatic carcinoma that lies within the BRCA2 region.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 5950-5954.	3.3	155
20	Comparative microarray analysis of microRNA expression profiles in primary cutaneous malignant melanoma, cutaneous malignant melanoma metastases, and benign melanocytic nevi. Cell and Tissue Research, 2013, 351, 85-98.	1.5	137
21	Application of fluorescence difference gel electrophoresis saturation labelling for the analysis of microdissected precursor lesions of pancreatic ductal adenocarcinoma. Proteomics, 2005, 5, 2665-2679.	1.3	127
22	Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for pancreatic and colorectal adenocarcinoma. International Journal of Cancer, 2013, 132, E48-57.	2.3	126
23	Bloodâ€based detection of <scp>RAS</scp> mutations to guide antiâ€<scp>EGFR</scp> therapy in colorectal cancer patients: concordance of results from circulating tumor <scp>DNA</scp> and tissueâ€based <scp>RAS</scp> testing. Molecular Oncology, 2017, 11, 208-219.	2.1	125
24	Circular RNA expression in cutaneous squamous cell carcinoma. Journal of Dermatological Science, 2016, 83, 210-218.	1.0	124
25	The miR-17-92 cluster counteracts quiescence and chemoresistance in a distinct subpopulation of pancreatic cancer stem cells. Gut, 2015, 64, 1936-1948.	6.1	123
26	Mutations of the DPC4/Smad4 gene in neuroendocrine pancreatic tumors. Oncogene, 1999, 18, 2367-2371.	2.6	118
27	Anticipation in familial pancreatic cancer. Gut, 2006, 55, 252-258.	6.1	112
28	MicroRNA-148a is down-regulated in human pancreatic ductal adenocarcinomas and regulates cell survival by targeting CDC25B. Laboratory Investigation, 2011, 91, 1472-1479.	1.7	106
29	Repression of KIAA1199 attenuates Wnt-signalling and decreases the proliferation of colon cancer cells. British Journal of Cancer, 2011, 105, 552-561.	2.9	106
30	Pancreatic Intraepithelial Neoplasia Revisited and Updated. Pancreatology, 2009, 9, 45-54.	0.5	102
31	Microarray analysis of microRNA expression in cutaneous squamous cell carcinoma. Journal of Dermatological Science, 2012, 68, 119-126.	1.0	98
32	MiR-93 Controls Adiposity via Inhibition of Sirt7 and Tbx3. Cell Reports, 2015, 12, 1594-1605.	2.9	95
33	Global microRNA expression profiling of microdissected tissues identifies miRâ€135b as a novel biomarker for pancreatic ductal adenocarcinoma. International Journal of Cancer, 2012, 131, E86-95.	2.3	90
34	Circular RNA expression in basal cell carcinoma. Epigenomics, 2016, 8, 619-632.	1.0	85
35	SMIF, a Smad4-interacting protein that functions as a co-activator in TGFÎ² signalling. Nature Cell Biology, 2002, 4, 181-190.	4.6	82
36	Prevalence of familial pancreatic cancer in Germany. International Journal of Cancer, 2004, 110, 902-906.	2.3	78

#	Article	IF	Citations
37	DPC4/SMAD4 mediated tumor suppression of colon carcinoma cells is associated with reduced urokinase expression. Oncogene, 1999, 18, 3152-3158.	2.6	73
38	Analysis of the Pancreatic Tumor Progression by a Quantitative Proteomic Approach and Immunhistochemical Validation. Journal of Proteome Research, 2009, 8, 1647-1656.	1.8	67
39	MicroRNAs in cerebrospinal fluid as biomarker for disease course monitoring in primary central nervous system lymphoma. Journal of Neuro-Oncology, 2012, 109, 239-244.	1.4	67
40	Claudin-4-targeted optical imaging detects pancreatic cancer and its precursor lesions. Gut, 2013, 62, 1034-1043.	6.1	67
41	Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy. A report of the AIO Colorectal Study Group. International Journal of Colorectal Disease, 2008, 23, 1033-1039.	1.0	64
42	Label-Free Raman Spectroscopic Imaging Monitors the Integral Physiologically Relevant Drug Responses in Cancer Cells. Analytical Chemistry, 2015, 87, 7297-7304.	3.2	60
43	Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination with Trametinib in KRAS-Mutant Pancreatic and Colorectal Cancer. Cancer Research, 2019, 79, 2367-2378.	0.4	60
44	Activation of odorant receptor in colorectal cancer cells leads to inhibition of cell proliferation and apoptosis. PLoS ONE, 2017, 12, e0172491.	1.1	60
45	A Novel Organometallic Re^I Complex with Favourable Properties for Bioimaging and Applicability in Solidâ€Phase Peptide Synthesis. ChemBioChem, 2011, 12, 371-376.	1.3	59
46	Circulating U2 Small Nuclear RNA Fragments as a Novel Diagnostic Tool for Patients with Epithelial Ovarian Cancer. Clinical Chemistry, 2014, 60, 206-213.	1.5	59
47	Molecular Genetics of Exocrine Pancreatic Neoplasms. Surgical Clinics of North America, 1995, 75, 857-869.	0.5	58
48	A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling. Gut, 2016, 65, 647-657.	6.1	57
49	Recent Discoveries in Cancer Genetics of Exocrine Pancreatic Neoplasia. Digestion, 1998, 59, 493-501.	1.2	51
50	Evaluation of the 4q32-34 Locus in European Familial Pancreatic Cancer. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 1948-1955.	1.1	50
51	Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer. Gut, 2021, 70, 743-760.	6.1	49
52	DPC4 gene mutation in colitis associated neoplasia.. Gut, 1997, 40, 120-122.	6.1	48
53	New insights in the composition of extracellular vesicles from pancreatic cancer cells: implications for biomarkers and functions. Proteome Science, 2014, 12, 50.	0.7	48
54	TNF-Î±-producing macrophages determine subtype identity and prognosis via AP1 enhancer reprogramming in pancreatic cancer. Nature Cancer, 2021, 2, 1185-1203.	5.7	46

#	Article	IF	Citations
55	Prevalence of BRCA2 and CDKN2a mutations in German familial pancreatic cancer families. Familial Cancer, 2010, 9, 335-343.	0.9	44
56	Automated Identification of Subcellular Organelles by Coherent Anti-Stokes Raman Scattering. Biophysical Journal, 2014, 106, 1910-1920.	0.2	43
57	Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for primary central nervous system lymphoma. Neuro-Oncology, 2016, 18, 361-367.	0.6	42
58	Tumor suppressor Smad4 mediates downregulation of the anti-adhesive invasion-promoting matricellular protein SPARC: Landscaping activity of Smad4 as revealed by aâ€œsecretomeâ€•analysis. Proteomics, 2004, 4, 1324-1334.	1.3	41
59	A genetic roadmap of pancreatic cancer: still evolving. Gut, 2017, 66, 2170-2178.	6.1	41
60	RNASEL germline variants are associated with pancreatic cancer. International Journal of Cancer, 2005, 117, 718-722.	2.3	39
61	Pancreatic Expression database: a generic model for the organization, integration and mining of complex cancer datasets. BMC Genomics, 2007, 8, 439.	1.2	38
62	Asymmetric rhenium tricarbonyl complexes show superior luminescence properties in live cell imaging. Chemical Communications, 2017, 53, 905-908.	2.2	36
63	Systematic Comparison of Label-Free, SILAC, and TMT Techniques to Study Early Adaption toward Inhibition of EGFR Signaling in the Colorectal Cancer Cell Line DiFi. Journal of Proteome Research, 2020, 19, 926-937.	1.8	36
64	Update of Familial Pancreatic Cancer in Germany. Pancreatology, 2001, 1, 510-516.	0.5	35
65	Smad4 deficiency in cervical carcinoma cells. Oncogene, 2005, 24, 810-819.	2.6	35
66	Keratin23 (KRT23) Knockdown Decreases Proliferation and Affects the DNA Damage Response of Colon Cancer Cells. PLoS ONE, 2013, 8, e73593.	1.1	35
67	Long-noncoding RNAs in basal cell carcinoma. Tumor Biology, 2016, 37, 10595-10608.	0.8	35
68	A MicroRNA-Based Test Improves Endoscopic Ultrasoundâ€“Guided Cytologic Diagnosis of Pancreatic Cancer. Clinical Gastroenterology and Hepatology, 2014, 12, 1717-1723.	2.4	34
69	Circulating U2 small nuclear RNA fragments as a diagnostic and prognostic biomarker in lung cancer patients. Journal of Cancer Research and Clinical Oncology, 2016, 142, 795-805.	1.2	34
70	Characterization of a dual <scp>BET</scp>/<scp>HDAC</scp> inhibitor for treatment of pancreatic ductal adenocarcinoma. International Journal of Cancer, 2020, 147, 2847-2861.	2.3	34
71	Multimodal Treatment Eliminates Cancer Stem Cells and Leads to Long-Term Survival in Primary Human Pancreatic Cancer Tissue Xenografts. PLoS ONE, 2013, 8, e66371.	1.1	33
72	aRNA-longSAGE: a new approach to generate SAGE libraries from microdissected cells. Nucleic Acids Research, 2004, 32, e131-e131.	6.5	32

#	Article	IF	Citations
73	Low Frequency of CHEK2 Mutations in Familial Pancreatic Cancer. Familial Cancer, 2006, 5, 305-308.	0.9	32
74	Lack of CCR7 expression is rate limiting for lymphatic spread of pancreatic ductal adenocarcinoma. International Journal of Cancer, 2012, 131, E371-81.	2.3	31
75	TFEB-mediated lysosomal biogenesis and lysosomal drug sequestration confer resistance to MEK inhibition in pancreatic cancer. Cell Death Discovery, 2020, 6, 12.	2.0	30
76	The Pancreatic Expression database: 2011 update. Nucleic Acids Research, 2011, 39, D1023-D1028.	6.5	29
77	In vitro prediction of the efficacy of molecularly targeted cancer therapy by Raman spectral imaging. Analytical and Bioanalytical Chemistry, 2015, 407, 8321-8331.	1.9	29
78	Keratin 23, a novel DPC4/Smad4 target gene which binds 14-3-3Îµ. BMC Cancer, 2011, 11, 137.	1.1	28
79	The pancreatic expression database: recent extensions and updates. Nucleic Acids Research, 2014, 42, D944-D949.	6.5	28
80	Expression profiles of long noncoding RNAs in cutaneous squamous cell carcinoma. Epigenomics, 2016, 8, 501-518.	1.0	26
81	MicroRNA-30c as a novel diagnostic biomarker for primary and secondary B-cell lymphoma of the CNS. Journal of Neuro-Oncology, 2018, 137, 463-468.	1.4	26
82	Raman micro-spectroscopy monitors acquired resistance to targeted cancer therapy at the cellular level. Scientific Reports, 2018, 8, 15278.	1.6	26
83	Digital-Droplet PCR for Quantification of CD19-Directed CAR T-Cells. Frontiers in Molecular Biosciences, 2020, 7, 84.	1.6	26
84	Clinical and genetic analysis of 18 pancreatic carcinoma/melanomaâ€prone families. Clinical Genetics, 2010, 77, 333-341.	1.0	25
85	Deregulated miR-29b-3p Correlates with Tissue-Specific Activation of Intrinsic Apoptosis in An Animal Model of Amyotrophic Lateral Sclerosis. Cells, 2019, 8, 1077.	1.8	25
86	Norepinephrine inhibits the migratory activity of pancreatic cancer cells. Experimental Cell Research, 2013, 319, 1744-1758.	1.2	24
87	A Soluble Form of the Giant Cadherin Fat1 Is Released from Pancreatic Cancer Cells by ADAM10 Mediated Ectodomain Shedding. PLoS ONE, 2014, 9, e90461.	1.1	24
88	German National Case Collection of Familial Pancreatic Cancer â€“ Clinical-Genetic Analysis of the First 21 Families. Oncology Research and Treatment, 2002, 25, 262-266.	0.8	21
89	Unveiling of miRNA Expression Patterns in Purkinje Cells During Development. Cerebellum, 2017, 16, 376-387.	1.4	19
90	Comparative analysis of cell death induction by Taurolidine in different malignant human cancer cell lines. Journal of Experimental and Clinical Cancer Research, 2010, 29, 21.	3.5	18

#	Article	IF	Citations
91	Analysis of U2 Small Nuclear RNA Fragments in the Bile Differentiates Cholangiocarcinoma from Primary Sclerosing Cholangitis and Other Benign Biliary Disorders. Digestive Diseases and Sciences, 2014, 59, 1436-1441.	1.1	18
92	Suppression of soluble adenylyl cyclase protects smooth muscle cells against oxidative stress-induced apoptosis. Apoptosis: an International Journal on Programmed Cell Death, 2014, 19, 1069-1079.	2.2	18
93	The NOD2 3020insC Mutation and The Risk of Familial Pancreatic Cancer?. Hereditary Cancer in Clinical Practice, 2004, 2, 149.	0.6	16
94	Clonal T-cell populations are frequent in the skin and blood of patients with systemic sclerosis. British Journal of Dermatology, 2009, 161, 785-790.	1.4	15
95	Induction of pancreatic cancer cell migration by an autocrine epidermal growth factor receptor activation. Experimental Cell Research, 2014, 326, 307-314.	1.2	15
96	Activation leads to a significant shift in the intracellular redox homeostasis of neutrophil-like cells. Redox Biology, 2020, 28, 101344.	3.9	15
97	Divergent mechanisms underlie Smad4-mediated positive regulation of the three genes encoding the basement membrane component laminin-332 (laminin-5). BMC Cancer, 2008, 8, 215.	1.1	14
98	Gene expression analysis of cell death induction by Taurolidine in different malignant cell lines. BMC Cancer, 2010, 10, 595.	1.1	14
99	Exploring the efficacy and cellular uptake of sorafenib in colon cancer cells by Raman micro-spectroscopy. Analyst, The, 2018, 143, 6069-6078.	1.7	13
100	Molecular pathogenesis of pancreatic cancer. Hematology/Oncology Clinics of North America, 2002, 16, 17-35.	0.9	11
101	Lentiviral Overexpression of miRNAs. Methods in Molecular Biology, 2014, 1095, 177-190.	0.4	11
102	Innovative substance 2250 as a highly promising anti-neoplastic agent in malignant pancreatic carcinoma - in vitro and in vivo. BMC Cancer, 2017, 17, 216.	1.1	11
103	Alterations in pectoralis muscle cell characteristics after radiation of the human breast in situ. Journal of Radiation Research, 2019, 60, 825-830.	0.8	11
104	Altered T-Lymphocyte Biology Following High-Dose Melphalan and Autologous Stem Cell Transplantation With Implications for Adoptive T-Cell Therapy. Frontiers in Oncology, 2020, 10, 568056.	1.3	11
105	Detection of Clonal T Cells in the Circulation of Patients With Nephrogenic Systemic Fibrosis. Archives of Dermatology, 2009, 145, 1164-9.	1.7	10
106	Unveiling Luminescent Ir^I and Rh^I Nâ€Heterocyclic Carbene Complexes: Structure, Photophysical Specifics, and Cellular Localization in the Endoplasmic Reticulum. Chemistry - A European Journal, 2021, 27, 6783-6794.	1.7	10
107	Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models. Genome Medicine, 2021, 13, 116.	3.6	10
108	Deficiency of myostatin protects skeletal muscle cells from ischemia reperfusion injury. Scientific Reports, 2021, 11, 12572.	1.6	9

#	Article	IF	Citations
109	Where and When Does Pancreatic Carcinoma Start?. Medizinische Klinik, 2004, 99, 191-195.	0.5	8
110	High-level inducible Smad4-reexpression in the cervical cancer cell line C4-II is associated with a gene expression profile that predicts a preferential role of Smad4 in extracellular matrix composition. BMC Cancer, 2007, 7, 209.	1.1	8
111	Discarding duplicate ditags in LongSAGE analysis may introduce significant error. BMC Bioinformatics, 2007, 8, 92.	1.2	8
112	A Web-Based Platform for Mining Pancreatic Expression Datasets. Pancreatology, 2009, 9, 340-343.	0.5	7
113	Quantitative RT-PCR Specific for Precursor and Mature miRNAs. Methods in Molecular Biology, 2014, 1095, 121-134.	0.4	7
114	TGFâ€beta pathway inhibition as the therapeutic acceleration of diabetic bone regeneration. Journal of Orthopaedic Research, 2022, 40, 1810-1826.	1.2	7
115	Differential proteome analysis of colon carcinoma cell line SW480 after reconstitution of the tumour suppressor Smad4. Analytical and Bioanalytical Chemistry, 2006, 386, 1603-1612.	1.9	6
116	Application of Fluorescence Dye Saturation Labeling for Differential Proteome Analysis of 1,000 Microdissected Cells from Pancreatic Ductal Adenocarcinoma Precursor Lesions. Methods in Molecular Biology, 2008, 425, 1-14.	0.4	6
117	Nuclear spheres modulate the expression of BEST1 and GADD45G. Cellular Signalling, 2016, 28, 100-109.	1.7	5
118	Metabolism-based GP-2250 in combination with gemcitabine as a novel approach to pancreatic cancer: A mouse xenograft study.. Journal of Clinical Oncology, 2020, 38, e16750-e16750.	0.8	5
119	Genetics of hereditary pancreatic carcinoma. Gastroenterology Clinics of North America, 2004, 33, 919-934.	1.0	4
120	Microcapsules: Reverse Sonoporation and Long-lasting, Safe Contrast. Acoustical Imaging, 2012, , 81-90.	0.2	4
121	HNPCC: Six new pathogenic mutations. BMC Medical Genetics, 2004, 5, 16.	2.1	3
122	Genetics of Hereditary Pancreatic Carcinoma. Clinics in Laboratory Medicine, 2005, 25, 117-133.	0.7	3
123	Monitoring and modeling of microbubble behavior during ultrasound mediated transfection of cell monolayers. , 2008, , .		3
124	Disabling VEGF-Response of Purkinje Cells by Downregulation of KDR via miRNA-204-5p. International Journal of Molecular Sciences, 2021, 22, 2173.	1.8	3
125	Manual Microdissection Combined with Antisense RNAâ€“LongSAGE for the Analysis of Limited Cell Numbers. Methods in Molecular Biology, 2009, 576, 135-154.	0.4	3
126	De novo expression of gastrokines in pancreatic precursor lesions impede the development of pancreatic cancer. Oncogene, 2022, 41, 1507-1517.	2.6	3

#	Article	IF	Citations
127	New Therapy Options for Neuroendocrine Carcinoma of the Pancreasâ€"The Emergent Substance GP-2250 and Gemcitabine Prove to Be Highly Effective without the Development of Secondary Resistances In Vitro and In Vivo. Cancers, 2022, 14, 2685.	1.7	3
128	Molecular genetics of pancreatic carcinoma. Cancer Genetics and Cytogenetics, 1995, 84, 130.	1.0	2
129	Microsatellite instability and expression of MLH1 and MSH2 in carcinomas of the small intestine. Cancer, 2003, 98, 1774-1775.	2.0	2
130	EU Pancreas: An Integrated European Platform for Pancreas Cancer Research - from Basic Science to Clinical and Public Health Interventions for a Rare Disease. Public Health Genomics, 2013, 16, 305-312.	0.6	2
131	DPC4/Smad4 mediated tumor suppression in pancreatic cancer cells through suppression of angiogenesis. Gastroenterology, 2000, 118, A50.	0.6	1
132	Gibt es Perspektiven zur Frï¿½herkennung des Pankreaskarzinoms?. Der Pathologe, 2005, 26, 11-11.	0.7	1
133	Abstract 4678: KIAA1199 depletion targets the wnt/beta catenin signaling pathway and impairs migration and proliferation of human colon cancer cells. , 2010, , .		1
134	Abstract 4132:MicroRNA-1246 as a novel candidate for a blood-based biomarker in ovarian cancer patients. , 2012, , .		1
135	Robust adaption algorithm for effective and safe sonoporation therapy. Biomedizinische Technik, 2012, 57, .	0.9	0
136	Pankreaskarzinom. , 2002, , 187-206.		0
137	U2 Small Nuclear RNA as a Biomarker in Cancer. , 2014, , 1-15.		0
138	Abstract 1873: Drivers of secondary resistance to anti-EGFR therapy in metastatic colorectal cancer. , 2020, , .		0